| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
45,103 |
41,621 |
$7.72M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
52,079 |
46,923 |
$686K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,174 |
18,223 |
$428K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
10,069 |
8,881 |
$368K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,805 |
3,629 |
$196K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,921 |
2,902 |
$111K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,413 |
4,097 |
$55K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,275 |
3,984 |
$48K |
| 0259 |
|
4,377 |
4,249 |
$42K |
| G0071 |
Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only |
1,752 |
1,622 |
$39K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
327 |
315 |
$36K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
859 |
857 |
$25K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
532 |
519 |
$25K |
| 90686 |
|
1,368 |
1,368 |
$16K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,370 |
2,348 |
$13K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,188 |
1,156 |
$10K |
| 0250 |
|
1,250 |
1,172 |
$10K |
| 80053 |
Comprehensive metabolic panel |
2,106 |
1,953 |
$9K |
| 99221 |
|
574 |
447 |
$9K |
| 0636 |
|
951 |
942 |
$8K |
| 76641 |
|
882 |
757 |
$8K |
| 87581 |
|
536 |
521 |
$8K |
| 87486 |
|
536 |
521 |
$8K |
| 82948 |
|
6,320 |
5,919 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,732 |
1,678 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,385 |
2,219 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,592 |
1,530 |
$7K |
| 99000 |
|
3,175 |
3,030 |
$6K |
| 0761 |
|
959 |
726 |
$6K |
| 81003 |
|
4,814 |
4,497 |
$6K |
| 0361 |
|
55 |
54 |
$5K |
| 80061 |
Lipid panel |
675 |
673 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
703 |
676 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
549 |
546 |
$4K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
1,308 |
746 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
397 |
392 |
$4K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
714 |
694 |
$4K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
266 |
266 |
$4K |
| 87077 |
|
931 |
912 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
343 |
342 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
956 |
941 |
$3K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
16 |
16 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
522 |
520 |
$3K |
| 59425 |
|
59 |
38 |
$2K |
| J3490 |
Unclassified drugs |
2,248 |
1,579 |
$2K |
| 81025 |
|
1,123 |
1,072 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
81 |
78 |
$2K |
| 99215 |
Prolong outpt/office vis |
49 |
49 |
$2K |
| 87186 |
|
323 |
316 |
$2K |
| 87070 |
|
292 |
289 |
$2K |
| 0710 |
|
644 |
531 |
$2K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
26 |
26 |
$1K |
| 90670 |
|
12 |
12 |
$1K |
| 51798 |
|
142 |
139 |
$1K |
| 81001 |
|
1,051 |
959 |
$1K |
| 92552 |
|
121 |
121 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,107 |
859 |
$980.81 |
| 99201 |
|
82 |
82 |
$927.78 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
41 |
41 |
$787.96 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
85 |
78 |
$744.80 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
69 |
68 |
$699.58 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
33 |
32 |
$614.21 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
12 |
12 |
$564.41 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
376 |
343 |
$520.53 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
177 |
171 |
$449.28 |
| E0114 |
Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips |
12 |
12 |
$415.25 |
| A4217 |
Sterile water/saline, 500 ml |
472 |
367 |
$348.00 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
141 |
139 |
$337.72 |
| 20610 |
|
25 |
25 |
$312.95 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
91 |
82 |
$262.53 |
| Q3014 |
Telehealth originating site facility fee |
13 |
12 |
$229.40 |
| 99443 |
|
74 |
72 |
$223.84 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
553 |
517 |
$223.48 |
| 73610 |
|
14 |
14 |
$218.92 |
| 0271 |
|
27 |
26 |
$209.17 |
| 59025 |
Fetal non-stress test |
1,182 |
598 |
$209.10 |
| 73630 |
|
12 |
12 |
$188.88 |
| 86580 |
|
105 |
102 |
$154.56 |
| 73140 |
|
13 |
13 |
$147.83 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
268 |
250 |
$144.56 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
34 |
30 |
$110.11 |
| 99173 |
|
80 |
80 |
$90.91 |
| A4649 |
Surgical supply; miscellaneous |
645 |
401 |
$72.54 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
24 |
24 |
$67.61 |
| J2704 |
Injection, propofol, 10 mg |
96 |
89 |
$49.40 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
392 |
381 |
$39.16 |
| J7050 |
Infusion, normal saline solution, 250 cc |
313 |
196 |
$37.85 |
| 99442 |
|
157 |
150 |
$31.43 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
504 |
410 |
$16.91 |
| 81015 |
|
97 |
95 |
$11.65 |
| 82570 |
|
15 |
13 |
$11.04 |
| 84550 |
|
12 |
12 |
$10.43 |
| 83690 |
|
14 |
13 |
$7.11 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
514 |
422 |
$5.24 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
284 |
244 |
$2.58 |
| 36415 |
Collection of venous blood by venipuncture |
1,480 |
1,281 |
$0.00 |
| A9270 |
Non-covered item or service |
286 |
267 |
$0.00 |
| Z7610 |
|
1,995 |
1,641 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
320 |
316 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
25 |
16 |
$0.00 |
| 0370 |
|
132 |
124 |
$0.00 |
| 85730 |
|
27 |
27 |
$0.00 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
27 |
27 |
$0.00 |
| 0270 |
|
312 |
266 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
83 |
53 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
40 |
40 |
$0.00 |
| X6218 |
|
176 |
176 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
271 |
205 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
206 |
206 |
$0.00 |
| 93000 |
|
13 |
13 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
23 |
18 |
$0.00 |
| Z1034 |
|
22 |
12 |
$0.00 |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
12 |
12 |
$0.00 |
| 0272 |
|
476 |
364 |
$0.00 |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
138 |
134 |
$0.00 |
| 85610 |
|
42 |
41 |
$0.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
609 |
604 |
$0.00 |
| 90461 |
|
234 |
234 |
$0.00 |
| 88312 |
|
28 |
28 |
$0.00 |
| 77066 |
Tomosynthesis, mammo |
61 |
61 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
99 |
85 |
$0.00 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
12 |
12 |
$0.00 |
| 77062 |
|
33 |
33 |
$0.00 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
29 |
29 |
$0.00 |
| J1756 |
Injection, iron sucrose, 1 mg |
60 |
30 |
$0.00 |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
13 |
$0.00 |
| 0360 |
|
13 |
13 |
$0.00 |
| 0750 |
|
29 |
26 |
$0.00 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
12 |
12 |
$0.00 |